PD-1 knockout engineered T cells (Cell Biotech)

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NamePD-1 knockout engineered T cells (Cell Biotech)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionT lymphocyte replacementsProgrammed cell death protein 1 blockers

TargetsProgrammed cell death protein 1

Therapy Area/IndicationsUrinary Bladder NeoplasmsCarcinoma, Renal Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaDiscontinued

Originator CompaniesCell Biotech

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPeking University

Active IndicationsN/A

Inactive IndicationsUrinary Bladder NeoplasmsCarcinoma, Renal Cell

Other Information

ATC CodeN/A